Solagran International

Solagran is a biotechnology company that specialized in the development of Bioeffectives, a class of biologically active substances extracted from live conifer needles. The company's primary focus was the commercialization of Ropren (Bioeffective A), a polyprenol-based treatment approved in Russia for liver diseases including hepatitis and cirrhosis. Beyond hepatology, Solagran conducted extensive research into the neuroprotective properties of its compounds for indications such as Alzheimer's disease and Parkinson's disease. Although the company achieved significant regulatory success in Russia and was previously listed on the Australian Securities Exchange, it underwent financial restructuring and its technology is now associated with Prenolica. The company's core technology is based on decades of research into the therapeutic potential of the Siberian Taiga's flora.